IPERION (IPR) H2 2025 earnings summary

Executive summary

• Reported a net loss of $444,433 for the year ended 31 March 2025, a 46% improvement from the prior year's net loss of $822,259.

• Operations focused on product trials and marketing Pathoglaze for various antimicrobial applications.

• Sufficient cash reserves to cover costs for the next 12 months based on forecasts with no sales.

Financial highlights

• Total revenue from continuing operations was $0, unchanged from the previous year.

• Net loss reduced to $444,433 from $822,259 year-over-year.

• Manufacturing plant expenses decreased to $150,000 from $500,000 due to discounts and research grants.

• Administrative expenses fell to $306,531 from $354,372, mainly due to lower stock exchange and trade fair costs.

• Cash and cash equivalents increased to $425,341 from $168,647 year-over-year.

Outlook and guidance

• Focus remains on converting product trials into long-term sales agreements.

• Manufacturing plant operator agreed to fully discount the $400,000 fixed fee for the next financial year; direct production costs may apply when sales begin.